ACRV
NASDAQAcrivon Therapeutics Inc.
Price$1.44-0.02 (-1.71%)
01:30 PM07:00 PM
News · 26 weeks70+144%
2025-12-142026-06-07
Mix3990d
- Insider22(56%)
- Other9(23%)
- SEC Filings8(21%)
Latest news
25 items- INSIDERPresident and CEO Blume-Jensen Peter covered exercise/tax liability with 13,729 shares (SEC Form 4) to satisfy tax liability4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECSEC Form DEFA14A filed by Acrivon Therapeutics Inc.DEFA14A - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- PRAcrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation SummitWATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat on Tuesday, May 26, 2026, at 9:00 a.m. ET at TD Cowen's 7th Annual Oncology Innovation Summit. The live and archived webcast of this event can be accesse
- INSIDERDirector Ra Capital Management, L.P. was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Shacham Sharon was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Tomsicek Michael John was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Palani Santhosh was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Magovcevic-Liebisch Ivana was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Dirocco Derek was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERDirector Baum Charles M was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Accounting Officer Peterson Katharine was granted 14,227 shares, increasing direct ownership by 364% to 18,134 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Medical Officer Mirza Mansoor Raza was granted 38,817 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Legal Officer Miller Mary was granted 49,830 shares, increasing direct ownership by 151% to 82,767 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Financial Officer Levy Adam D. was granted 46,167 shares, increasing direct ownership by 220% to 67,150 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERPresident and CEO Blume-Jensen Peter was granted 252,801 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Development Officer Gamelin Erick was granted 38,584 shares, increasing direct ownership by 268% to 52,992 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Operating Officer Devroe Eric was granted 72,981 shares, increasing direct ownership by 99% to 146,953 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 3,907 units (SEC Form 4) (for tax liability)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Development Officer Gamelin Erick covered exercise/tax liability with 404 shares, decreasing direct ownership by 3% to 14,408 units (SEC Form 4) to cover taxes4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.56% to 32,937 units (SEC Form 4) to cover taxes4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Operating Officer Devroe Eric covered exercise/tax liability with 613 shares, decreasing direct ownership by 0.82% to 73,972 units (SEC Form 4) (withholding obligation)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERPresident and CEO Blume-Jensen Peter covered exercise/tax liability with 1,743 shares (SEC Form 4) (tax withholding)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Acrivon Therapeutics Inc.SCHEDULE 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
- PRAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of May 15, 2026. The employee received an aggregate of options to purchase 111,150 shares of Acrivon commo
- SECSEC Form 10-Q filed by Acrivon Therapeutics Inc.10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
ACRV FAQ
6 questionsWhere does ACRV stock trade?
Acrivon Therapeutics Inc. (ACRV) is listed on NASDAQ.What sector and industry is ACRV in?
Acrivon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Acrivon Therapeutics Inc. go public?
Acrivon Therapeutics Inc. (ACRV) completed its IPO in 2022.What are analysts saying about ACRV?
Acrivon Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $600.00 price target on 2025-05-05. Recent price targets range from $600.00 to $2500.00.What companies are similar to ACRV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ACRV side-by-side with any of them on Quantisnow.How can I track ACRV on Quantisnow?
Quantisnow aggregates Acrivon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACRV to receive live email and push alerts on every new disclosure.